| Wissenschaftl. Titel | A Phase III, multicenter, randomized, open-Label Trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant Treatment in patients with Hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib (LEE011): NATALEE). |
| Erkrankung |
Geschlechtsorgane:
Brustkrebs:
adjuvant
|
| Molekularer Marker |
HER2/neu neg. PR HER2/neu neg./ER pos. ER HER2/neu neg./PR pos. |
|
Agaplesion Markus Krankenhaus
(Geschlossen) PD Dr. med. Marc Thill Tel: 069 / 95332228 Fax: 069 / 95332733 marc.thill@fdk.info |
|
| Kurzprotokoll | Kurzprotokoll |
erstellt 24.02.2020 Student Studienregister
geändert 17.02.2022 Student Studienregister